<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1887-8571</journal-id>
<journal-title><![CDATA[Sanidad Militar]]></journal-title>
<abbrev-journal-title><![CDATA[Sanid. Mil.]]></abbrev-journal-title>
<issn>1887-8571</issn>
<publisher>
<publisher-name><![CDATA[Ministerio de Defensa]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1887-85712017000300162</article-id>
<article-id pub-id-type="doi">10.4321/s1887-85712017000300005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Evaluación positiva de medicamentos: marzo, abril y mayo 2017]]></article-title>
<article-title xml:lang="en"><![CDATA[Possitive assessment of drugs: March, April and May 2017]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aparicio Hernández]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Puerro Vicente]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cabanes Mariscal]]></surname>
<given-names><![CDATA[MªA.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Prats Olivan]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacología Clínica ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacología Clínica ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Central de la Defensa Gómez Ulla Servicio de Farmacia Hospitalaria ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2017</year>
</pub-date>
<volume>73</volume>
<numero>3</numero>
<fpage>162</fpage>
<lpage>172</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1887-85712017000300162&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1887-85712017000300162&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1887-85712017000300162&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Se reseñan los medicamentos evaluados y con dictamen positivo por comisión de expertos de la Agencia Española de Medicamentos y Productos Sanitarios o de la Agencia Europea del Medicamento hechos públicos en marzo, abril y mayo 2017, y considerados de mayor interés para el profesional sanitario. Se trata de opiniones técnicas positivas que son previas a la autorización y puesta en el mercado del medicamento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[SUMMARY The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2017, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Beclometasona Dipropionato / Formoterol / Glicopirronio Bromuro]]></kwd>
<kwd lng="es"><![CDATA[Trimbow®]]></kwd>
<kwd lng="es"><![CDATA[Brodalumab]]></kwd>
<kwd lng="es"><![CDATA[Kyntheum®]]></kwd>
<kwd lng="es"><![CDATA[Cariprazina]]></kwd>
<kwd lng="es"><![CDATA[Reagila®]]></kwd>
<kwd lng="es"><![CDATA[Cenegermin]]></kwd>
<kwd lng="es"><![CDATA[Oxervate®]]></kwd>
<kwd lng="es"><![CDATA[Cerliponasa Alfa]]></kwd>
<kwd lng="es"><![CDATA[Brineura®]]></kwd>
<kwd lng="es"><![CDATA[Condrocitos Humanos Autólogos Asociados a Matriz]]></kwd>
<kwd lng="es"><![CDATA[Spherox®]]></kwd>
<kwd lng="es"><![CDATA[Dinutuximab Beta]]></kwd>
<kwd lng="es"><![CDATA[Dinutuximab Beta Apeiron®]]></kwd>
<kwd lng="es"><![CDATA[Etanercept]]></kwd>
<kwd lng="es"><![CDATA[Erelzi®]]></kwd>
<kwd lng="es"><![CDATA[Fluciclovina]]></kwd>
<kwd lng="es"><![CDATA[18f Axumin®]]></kwd>
<kwd lng="es"><![CDATA[Fumarato Dimetilo]]></kwd>
<kwd lng="es"><![CDATA[Skilarence®]]></kwd>
<kwd lng="es"><![CDATA[Inotuzumab Ozogamicina]]></kwd>
<kwd lng="es"><![CDATA[Besponsa®]]></kwd>
<kwd lng="es"><![CDATA[Nonacog Beta Pegol]]></kwd>
<kwd lng="es"><![CDATA[Refixia®]]></kwd>
<kwd lng="es"><![CDATA[Nusinersen]]></kwd>
<kwd lng="es"><![CDATA[Spinraza®]]></kwd>
<kwd lng="es"><![CDATA[Patirómero]]></kwd>
<kwd lng="es"><![CDATA[Veltassa®]]></kwd>
<kwd lng="es"><![CDATA[Pentosano Polisulfato de Sodio]]></kwd>
<kwd lng="es"><![CDATA[Elmiron®]]></kwd>
<kwd lng="es"><![CDATA[Rituximab]]></kwd>
<kwd lng="es"><![CDATA[Rixathon®]]></kwd>
<kwd lng="es"><![CDATA[Riximyo®]]></kwd>
<kwd lng="es"><![CDATA[Sarilumab]]></kwd>
<kwd lng="es"><![CDATA[Kevzara®]]></kwd>
<kwd lng="es"><![CDATA[Trientina Tetraclorhidrato]]></kwd>
<kwd lng="es"><![CDATA[Cuprior®]]></kwd>
<kwd lng="es"><![CDATA[Vacuna Meningocócica del Grupo B]]></kwd>
<kwd lng="es"><![CDATA[Adnr]]></kwd>
<kwd lng="es"><![CDATA[Adsorbida]]></kwd>
<kwd lng="es"><![CDATA[Trumenba®]]></kwd>
<kwd lng="en"><![CDATA[Beclometasona Dipropionato / Formoterol / Glicopirronio Bromuro]]></kwd>
<kwd lng="en"><![CDATA[Trimbow®]]></kwd>
<kwd lng="en"><![CDATA[Brodalumab]]></kwd>
<kwd lng="en"><![CDATA[Kyntheum®]]></kwd>
<kwd lng="en"><![CDATA[Cariprazina]]></kwd>
<kwd lng="en"><![CDATA[Reagila®]]></kwd>
<kwd lng="en"><![CDATA[Cenegermin]]></kwd>
<kwd lng="en"><![CDATA[Oxervate®]]></kwd>
<kwd lng="en"><![CDATA[Cerliponasa Alfa]]></kwd>
<kwd lng="en"><![CDATA[Brineura®]]></kwd>
<kwd lng="en"><![CDATA[Condrocitos Humanos Autólogos Asociados a Matriz]]></kwd>
<kwd lng="en"><![CDATA[Spherox®]]></kwd>
<kwd lng="en"><![CDATA[Dinutuximab Beta]]></kwd>
<kwd lng="en"><![CDATA[Dinutuximab Beta Apeiron®]]></kwd>
<kwd lng="en"><![CDATA[Etanercept]]></kwd>
<kwd lng="en"><![CDATA[Erelzi®]]></kwd>
<kwd lng="en"><![CDATA[Fluciclovina]]></kwd>
<kwd lng="en"><![CDATA[18f Axumin®]]></kwd>
<kwd lng="en"><![CDATA[Fumarato Dimetilo]]></kwd>
<kwd lng="en"><![CDATA[Skilarence®]]></kwd>
<kwd lng="en"><![CDATA[Inotuzumab Ozogamicina]]></kwd>
<kwd lng="en"><![CDATA[Besponsa®]]></kwd>
<kwd lng="en"><![CDATA[Nonacog Beta Pegol]]></kwd>
<kwd lng="en"><![CDATA[Refixia®]]></kwd>
<kwd lng="en"><![CDATA[Nusinersen]]></kwd>
<kwd lng="en"><![CDATA[Spinraza®]]></kwd>
<kwd lng="en"><![CDATA[Patirómero]]></kwd>
<kwd lng="en"><![CDATA[Veltassa®]]></kwd>
<kwd lng="en"><![CDATA[Pentosano Polisulfato de Sodio]]></kwd>
<kwd lng="en"><![CDATA[Elmiron®]]></kwd>
<kwd lng="en"><![CDATA[Rituximab]]></kwd>
<kwd lng="en"><![CDATA[Rixathon®]]></kwd>
<kwd lng="en"><![CDATA[Riximyo®]]></kwd>
<kwd lng="en"><![CDATA[Sarilumab]]></kwd>
<kwd lng="en"><![CDATA[Kevzara®]]></kwd>
<kwd lng="en"><![CDATA[Trientina Tetraclorhidrato]]></kwd>
<kwd lng="en"><![CDATA[Cuprior®]]></kwd>
<kwd lng="en"><![CDATA[Vacuna Meningocócica del Grupo B]]></kwd>
<kwd lng="en"><![CDATA[Adnr]]></kwd>
<kwd lng="en"><![CDATA[Adsorbida]]></kwd>
<kwd lng="en"><![CDATA[Trumenba®]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios mayo 2017]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Papi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Corradi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Montagna]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cohuet]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Vezzoli]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Scuri]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Vestbo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single inhaler triple therapy versus inhaled corticosteroid plus long-acting &#946;2 agonist for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10048</numero>
<issue>10048</issue>
<page-range>963-73</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vestbo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Papi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Corradi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blazhko]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Montagna]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Francisco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2017</year>
<volume>389</volume>
<numero>10082</numero>
<issue>10082</issue>
<page-range>1919-29</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[Arznei-news]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<source><![CDATA[Medscape]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ensayan el primer tratamiento para la falta de emociones en las personas con esquizofrenia]]></article-title>
<source><![CDATA[Confederación Farmacéutica Argentina]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>NICE</collab>
<source><![CDATA[Cenegermin for treating neurotrophic keratitis [ID946]]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios abril 2017]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<collab>European Medicine Agency</collab>
<source><![CDATA[Product information. BRINEURA®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kohlschütter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schulz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis)]]></article-title>
<source><![CDATA[Pediatr Endocrinol Rev]]></source>
<year>2016</year>
<volume>13</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>682-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="">
<collab>European Medicine Agency</collab>
<source><![CDATA[Public assessment report. BRINEURA®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[New advanced therapy to repair cartilage defects in the knee]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)</collab>
<source><![CDATA[Informe mensual sobre Medicamentos de Uso Humano y Productos Sanitarios marzo 2017]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Dinutuximab beta Apeiron. EPAR summary for the public]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>European Medicine Agency</collab>
<source><![CDATA[EPAR summary for the public of Erelzi®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="">
<collab>European Medicine Agency</collab>
<source><![CDATA[EPAR of Erelzi®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Initial authorisation of Erelzi®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Griffiths]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Thaçi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gerdes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arenberger]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Pulka]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kingo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>2017</year>
<volume>176</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>928-38</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nanni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schiavina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brunocilla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Boschi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Borghesi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zanoni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pettinato]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martorana]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fanti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT]]></article-title>
<source><![CDATA[Clin Nucl Med]]></source>
<year>2015</year>
<volume>40</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>e386-91</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nanni]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Zanoni]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pultrone]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schiavina]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brunocilla]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Lodi]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Malizia]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rigatti]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Fonti]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Martorana]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Fanti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial]]></article-title>
<source><![CDATA[Eur J Nucl Med Mol Imaging]]></source>
<year>2016</year>
<volume>43</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1601-10</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<collab>EMA</collab>
<collab>Committee for Medicinal Products for Human Use (CHMP)</collab>
<source><![CDATA[Summary of opinion (initial authorisation) for Skilarence®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lijnen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Otters]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Balak]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Thio]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term safety and effectiveness of high-dose dimethylfumarate in the treatment of moderate to severe psoriasis: a prospective single-blinded follow-up study]]></article-title>
<source><![CDATA[J Dermatolog Treat]]></source>
<year>2016</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>31-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<collab>EMA</collab>
<collab>Committee for Medicinal Products for Human Use (CHMP)</collab>
<source><![CDATA[Public Assesment Report for Skilarence®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[Besponsa. Summary of opinion1 (initial authorisation)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<source><![CDATA[Committee for Orphan Medicinal Products (COMP)]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kantarjian]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[DeAngelo]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stelljes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martinelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Liedtke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Stock]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2016</year>
<volume>375</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>740-53</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="">
<source><![CDATA[Hemophilia News Today]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="">
<collab>EMA</collab>
<collab>Committee for Medicinal Products for Human Use (CHMP)</collab>
<source><![CDATA[Summary of opinion (initial authorisation) for Spinraza®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[EPAR for Spinraza®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoy]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nusinersen: First Global Approval]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2017</year>
<volume>77</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>473-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Montes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Finkel]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Motor milestone assessment of infants with spinal muscular atrophy using the hammersmith infant neurological Exam-Part 2: Experience from nusinersen clinical study]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="">
<source><![CDATA[First New Medicine for the Treatment of Hyperkalemia in More than 50 Years]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="">
<collab>Relypsa, Inc</collab>
<source><![CDATA[Veltassa label]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="">
<collab>U S Food and Drug Administration</collab>
<source><![CDATA[Elmiron® Label]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="">
<collab>EMA</collab>
<collab>Committee for Medicinal Products for Human Use (CHMP)</collab>
<source><![CDATA[Summary of opinion (initial authorisation) for Riximyo®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[CHMP summary of positive opinion for Rixathon®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Visser]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator Rituximab]]></article-title>
<source><![CDATA[BioDrugs]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>495-507</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[A da]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Target-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013]]></article-title>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>2014</year>
<volume>55</volume>
<page-range>1609-17</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="confpro">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wojciech]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moreira]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kanaka]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Munhoz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Echeveste]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Pratyush]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[A Phase III Efficacy and Safety Study of the Proposed Rituximab Biosimilar GP2013 Versus Rituximab in Patients with Previously Untreated Advanced Follicular Lymphoma]]></source>
<year></year>
<conf-name><![CDATA[ 58th anual meeting and exposition]]></conf-name>
<conf-loc>San Diego, CA </conf-loc>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="">
<collab>EMA</collab>
<collab>Committee for Medicinal Products for Human Use (CHMP)</collab>
<source><![CDATA[Summary of opinion-Initiala authorisation for Kevzara®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Genovese]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Fleischmann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kivitz]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rell Bakalarska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martincova]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fiore]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2015</year>
<volume>67</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1424-37</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[EPAR for Kevzara®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="">
<collab>EMA</collab>
<source><![CDATA[CHMP summary of positive opinion for Cuprior®]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="">
<collab>U S Food and Drug Administration</collab>
<source><![CDATA[Trumenba® Label]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
